Intermittent Fasting (IF/TRE) for Parkinson's Disease
Also known as: IF, Time-restricted eating, TRE, 16:8 fasting, 5:2 diet
IF activates autophagy for α-synuclein clearance and provides metabolic stress resistance for dopaminergic neurons.
Mechanism of Action
Fasting-induced autophagy clears α-synuclein aggregates, reduces neuroinflammation through SIRT1 activation, and provides BHB as mitochondrial fuel. It also activates BDNF expression for dopaminergic neuroplasticity.
General mechanism: Temporal caloric restriction. AMPK activation, mTOR inhibition, autophagy induction, SIRT1 activation, ketogenesis, differential stress resistance.
Current Evidence
Preclinical PD models show neuroprotection with IF. Human studies show improved metabolic parameters. PD-specific IF trials limited.
Clinical Status: Preclinical support. Human metabolic studies positive. PD trials emerging.
Safety Profile
Generally safe for healthy individuals. Contraindicated in eating disorders. ALS: caloric maintenance critical. Diabetics: medication adjustment needed.
Key Research Questions
- Can IF-induced autophagy reduce α-synuclein pathology in PD?
- Does TRE improve motor symptoms in PD patients?